Advances in research on potential inhibitors of multiple myeloma

被引：3
作者：
Tang, Guoyuan [1 ]
Huang, Shan [2 ,3 ]
Luo, Ji [4 ,5 ]
Wu, Yingmiao [4 ,5 ]
Zheng, Shuai [4 ,5 ]
Tong, Rongsheng [1 ,6 ]
Zhong, Ling [4 ,5 ,7 ]
Shi, Jianyou [1 ,6 ]
机构：
[1] Chengdu Univ Tradit Chinese Med, State Key Lab Southwestern Chinese Med Resources, Chengdu 611137, Peoples R China
[2] Univ Elect Sci & Technol China, Sichuan Acad Med Sci, Canc Ctr, Chengdu 610072, Sichuan, Peoples R China
[3] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Sch Med, Chengdu 610072, Sichuan, Peoples R China
[4] Univ Elect Sci & Technol China, Sichuan Acad Med Sci, Ctr Med Genet, Sichuan Prov Key Lab Human Dis Gene Study, Chengdu 610072, Sichuan, Peoples R China
[5] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Chengdu 610072, Sichuan, Peoples R China
[6] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Sch Med, Dept Pharm,Personalized Drug Therapy Key Lab Sichu, Chengdu 610072, Sichuan, Peoples R China
[7] Chinese Acad Sci, Chengdu Inst Biol, Chengdu 610041, Sichuan, Peoples R China
来源：
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 2023年 / 262卷
基金：
中国国家自然科学基金; 中国博士后科学基金;
关键词：
Multiple myeloma; Drug resistance; Potential drugs; Structure-activity relationships; UBIQUITIN-PROTEASOME-SYSTEM; TOLL-LIKE RECEPTORS; TARGETED PROTEIN-DEGRADATION; DRUG-RESISTANCE; DEUBIQUITINATING ENZYMES; NEDD8-ACTIVATING ENZYME; CELL-PROLIFERATION; KINASE; SUPPRESSES; ACTIVATION;
D O I：
10.1016/j.ejmech.2023.115875
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Multiple myeloma (MM) is a common hematological malignancy. Although recent clinical applications of immunomodulatory drugs, proteasome inhibitors and CD38-targeting antibodies have significantly improved the outcome of MM patient with increased survival, the incidence of drug resistance and severe treatment-related complications is gradually on the rise. This review article summarizes the characteristics and clinical investigations of several MM drugs in clinical trials, including their structures, mechanisms of action, structure activity relationships, and clinical study progress. Furthermore, the application potentials of the drugs that have not yet entered clinical trials are also reviewed. The review also outlines the future directions of MM drug development.
引用
收藏
页数：19
相关论文
共 228 条
  • [1] Immunotherapy of Multiple Myeloma: Promise and Challenges
    Abramson, Hanley N.
    [J]. IMMUNOTARGETS AND THERAPY, 2021, 10 : 343 - 371
  • [2] Toll-like receptors: New targets for multiple myeloma treatment?
    Akesolo, Olaia
    Buey, Berta
    Beltran-Visiedo, Manuel
    Giraldos, David
    Marzo, Isabel
    Latorre, Eva
    [J]. BIOCHEMICAL PHARMACOLOGY, 2022, 199
  • [3] BRD4: a general regulator of transcription elongation
    Altendorfer, Elisabeth
    Mochalova, Yelizaveta
    Mayer, Andreas
    [J]. TRANSCRIPTION-AUSTIN, 2022, 13 (1-3): : 70 - 81
  • [4] The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells
    Asano, J.
    Nakano, A.
    Oda, A.
    Amou, H.
    Hiasa, M.
    Takeuchi, K.
    Miki, H.
    Nakamura, S.
    Harada, T.
    Fujii, S.
    Kagawa, K.
    Endo, I.
    Yata, K.
    Sakai, A.
    Ozaki, S.
    Matsumoto, T.
    Abe, M.
    [J]. LEUKEMIA, 2011, 25 (07) : 1182 - 1188
  • [5] The nuclear export protein XPO1-from biology to targeted therapy
    Azmi, Asfar S.
    Uddin, Mohammed H.
    Mohammad, Ramzi M.
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2021, 18 (03) : 152 - 169
  • [6] Marizomib for central nervous system-multiple myeloma
    Badros, Ashraf
    Singh, Zeba
    Dhakal, Binod
    Kwok, Young
    MacLaren, Ann
    Richardson, Paul
    Trikha, Mohit
    Hari, Parameswaran
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2017, 177 (02) : 221 - 225
  • [7] Updates to the drug-resistant mechanism of proteasome inhibitors in multiple myeloma
    Bai, Yang
    Su, Xing
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 (01) : 29 - 35
  • [8] Ligand- and structure-based in silico studies to identify kinesin spindle protein (KSP) inhibitors as potential anticancer agents
    Balakumar, Chandrasekaran
    Ramesh, Muthusamy
    Tham, Chuin Lean
    Khathi, Samukelisiwe Pretty
    Kozielski, Frank
    Srinivasulu, Cherukupalli
    Hampannavar, Girish A.
    Sayyad, Nisar
    Soliman, Mahmoud E.
    Karpoormath, Rajshekhar
    [J]. JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2018, 36 (14) : 3687 - 3704
  • [9] Selective inhibition of nuclear export: a promising approach in the shifting treatment paradigms for hematological neoplasms
    Balasubramanian, Suresh Kumar
    Azmi, Asfar S.
    Maciejewski, Jaroslaw
    [J]. LEUKEMIA, 2022, 36 (03) : 601 - 612
  • [10] Overview of the membrane-associated RING-CH (MARCH) E3 ligase family
    Bauer, Johannes
    Bakke, Oddmund
    Morth, J. Preben
    [J]. NEW BIOTECHNOLOGY, 2017, 38 : 7 - 15
12345678910